Skip to main content
Publications
Brufsky A, Sandin R, Stergiopoulos S, Chen C, Karanth S , Li B, Esterberg L , Makari D, Candrilli S , Goyal R , Rugo H. Overall survival with palbociclib (PAL) plus an aromatase inhibitor (AI) versus AI alone in older patients (pts) with de novo, HR+/HER2− metastatic breast cancer: a SEER-Medicare analysis . Poster presented at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting; May 31, 2024. Chicago, IL.
Neal J, Lee JB, Ahn MJ, Ariyasu R, nash C, Smith D, Nagar S , Jimenez M , Kahangire DA, Kim YJ, Nasirova F, Lin S. Treatment (tx) patterns and clinical outcomes in unresectable stage III epidermal growth factor receptor-mutation positive (EGFRm) non-small cell lung cancer (NSCLC) treated with chemoradiotherapy (CRT): interim analysis of a global real-world (RW) study . Poster presented at the European Lung Cancer Congress (ELCC) 2024; March 20, 2024. Prague, Czech Republic.
Morris MJ, Armstrong AJ, Chi K, de Bono J, Herrmann K, Krause B, Rahbar K, Sartor O, Tagawa ST, Nagarajah J, Wei XX, Nordquist LT, Koshkin VS, Saad F, Vickers A , Ghouse R, Wu J, Mirante O, Fizazi K. Association of health-related quality of life with efficacy outcomes in the VISION study of patients with metastatic castration-resistant prostate cancer . Poster presented at the ESMO Congress 2023; October 22, 2023. Madrid, Spain.
Weber JS, Haque W, Markovic SN, Salama AKS, Mehmi I, Sullivan RJ, Najjar YG, Van Akkool A, Menzies A, Long G, Taylor AM, Haanen J, Zijlker L, Davis KL , Karanth S , Shah RM, Connolly L, Norton D. Relapse-free survival with adjuvant dabrafenib/trametinib therapy after relapse on a prior adjuvant checkpoint inhibitor and subsequent surgical resection in patients with BRAF V600–mutated stage III/IV melanoma . Poster presented at the ESMO Congress 2023; October 22, 2023. Madrid, Spain.
Goyal RK , Frugier G , Rombi J , Esterberg L , Davis KL , Hlavacek P, Ren J, Schepart A, Aydin D, DeBonaventura M. Treatment patterns of triple-class refractory (TCR) multiple myeloma (MM) across the United States (US), Canada, and western Europe: a real-world observational chart review study . Poster presented at the 2023 ASCO Annual Meeting; June 2, 2023. Chicago, IL.
Fasching PA, Hall PS, Chang L, Parikh R , Hitchens A , Davis KL , Sjekloca N, Summerhayes M, Ntalla I, Derrien Ansquer V , Bergamaco E, Ghabaireh M. Real-world clinical outcomes among patients (pts) with metastatic/advanced triple-negative breast cancer (mTNBC) in the United Kingdom (UK) and Germany (GER) . Poster presented at the 2023 ESMO Breast Cancer Annual Congress; May 11, 2023. Berlin, Germany.
Oikonomidou O, Galve-Calvo E, Wockel A, Parikh R , Hitchens A , Chen C, Gauthier E, Li B, Derrien Ansquer V , Frugier G , Jimenez M , Davis KL , Broughton EI. Real-world clinical outcomes associated with first-line palbociclib and aromatase inhibitor therapy among patients with HR+/HER2_ advanced breast cancer in Europe . Poster presented at the 2023 ESMO Breast Cancer Annual Congress; May 2023. Berlin, Germany.
Lin S, Kahangire DA, Nagar S , Ahn M, Affi R, Agulnik J, Shih J, Hockmair MJ, Tufman A, Debieuvre D, Chow J, Jimenez M , Davis KL , Sandelin M, Veluswamy R. Treatment (tx) patterns and outcomes in resectable early-stage non-small cell lung cancer (NSCLC): A global real-world (rw) study . Poster presented at the European Lung Cancer Congress 2023; March 31, 2023. Copenhagen, Demark.
Simmons DJ, Blank SV, Nagar S , Nham T , Long GH, Davis KL , Wetherill G, Munley J, McLaurin K. Real-world evaluation of PARP inhibitor tolerability in advanced ovarian cancer: retrospective US cohort study . Poster presented at the SGO 2023 Annual Meeting on Women's Cancer; March 27, 2023. Tampa, FL.
Shih JY, Lin SH, Nagar SP , Davis KL , Jimenez MI , Kahangire DA, Servidio L, Ho L, Veluswamy R. Treatment patterns in resectable early-stage NSCLC in Taiwan: subgroup analysis of a global real-world study . Poster presented at the 2022 ESMO Asia Congress; December 2, 2022. Singapore, Republic of Singapor.
Fernandez M, Bell TJ, Khan S , Tumminello B, Bektas M , Heyes CE , Oton AB. Burden of illness of desmoid tumors . Poster presented at the 2022 CTOS Annual Meeting; November 16, 2022. Vancouver, Canada. Previously presented at the 2022 Desmond Tumor Research Foundation (DTRF) Annual Meeting.
Veluswamy R, Ahn MJ, Nagar S , Affi R, Agulnik J, Shih JY, Hochmair MJ, Tufman A, Debieuvre D, Jimenez MI , Davis K , Kahangire DA, Servidio L, di Perna C, Lin SH. Surgical resection, treatment patterns and outcomes in patients (pts) with early-stage non-small cell lung cancer (NSCLC): interim analysis of a global real-world study . Poster presented at the 2022 International Thoracic Surgical Oncology Summit; September 30, 2022. New York, NY.
Spira A, Zhou X , Liao L, Yu E, Chen L, Lau A, Wang Y, Gnanasakthy A , Radford J, Hamadani M. Health-related quality of life and tolerability in patients with/without skin toxicity during loncastuximab tesirine treatment in a phase 2 clinical trial (LOTIS-2) . Poster presented at the Tenth Annual Meeting of the Society of Hematologic Oncology (SOHO 2022); September 28, 2022. Houston, TX.
Wainberg ZA, Enzinger PC, Qin S, Yamaguchi K, Gnanasakthy A , Taylor K, Jamotte A, Majer I, Kang YK. Health-related quality of life (HRQoL) in FGFR2b-overexpressing, advanced gastric or gastroesophageal junction cancer (G/GEJC): results from the FIGHT trial comparing bemarituzumab (BEMA) + modified FOLFOX6 (mFOLFOX6) to placebo (PBO) + mFOLFOX6 . Poster presented at the 2022 ESMO Annual Conference; September 9, 2022. Paris, France.
Diez-Campelo M, Yucel A, Goyal R , Parikh R , Dhuliawala S, Jimenez M , Sluga-O'Callaghan M , Hughes C, Tang D, Germing U. Systemic therapy utilization and hematologic outcomes in lower-risk myelodysplastic syndromes (LR-MDS): findings from a real-world medical record review study in the US, UK, and Europe (EU) . Poster presented at the 2022 European Hematology Association Hybrid Congress; June 10, 2022. Vienna, Austria.
Spira A, Liao L, Zhou X , Gnanasakthy A , Chen L, Ungar D, Yu E, Kilavuz T, Radford J, Hamadani M. Health-related quality of life and tolerability of loncastuximab tesirine in high-risk patients with relapsed/refractory diffuse large B-cell lymphoma treated in a phase 2 clinical trial (LOTIS 2) . Poster presented at the 2022 EHA Congress; June 9, 2022. Vienna, Austria.
Lin SH, Ahn M, Nagar S , Affi R, Agulnik J, Shih J, Hochmair MJ, Tufman A, Debieuvre D, Jimenez MI , Davis K , Kahangire DA, Servidio L, Veluswamy R. Treatment patterns and outcomes in resectable early stage NSCLC: interim analysis of a global real-world study . Poster presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting; June 3, 2022. Chicago, IL.
Spira A, Liao L, Zhou X , Sherif B , Chen L, Ungar D, Yu E, Radford J, Hamadani M. Health-related quality of life, symptoms, and tolerability of Loncastuximab Tesirine in older versus younger patients with relapsed/refractory diffuse large b-cell lymphoma treated in a phase 2 clinical trial (LOTIS-2) . Poster presented at the National Comprehensive Cancer Network (NCCN) 2022 Virtual Annual Conference; March 31, 2022.
Elimova E, Wyrwicz L, Blum SI, Xiao H, Li M, Kondo K, Davenport E , Wang J , Hunter S, Moehler MH. Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): results of nivolumab plus chemotherapy (NIVO+chemo) versus chemo from CheckMate 649 . Poster presented at the 2021 ASCO Quality Care Symposium; September 24, 2021.
Wolf J, Garon EB, Groen HJM, Tan DSW, Gilloteau I, Le Mouhaer S, Can C, Chassot-Agostinho A, Reynolds M , Odom D , Heist RS. Patient-reported outcomes in capmatinib-treated patients with METex14-mutated advanced NSCLC: results from the phase II GEOMETRY mono-1 study . Poster presented at the ASCO 2021 Annual Meeting; June 4, 2021.
Popat S, Tanna N, Hartridge-Lambert S, Kiff C, Sowdani A, Rothwell B, Brodtkorb T-H , Ling C , Smittenaar R, Bomb M, Turnbull A. Nivolumab in second line non-small cell lung cancer – comparing real-world outcomes in England to CheckMate (CM) 017 and 057 . Poster presented at the IASLC 2020 Virtual World Conference on Lung Cancer; January 28, 2021.
Arana A , Pottegard A, Kuiper JG, Crellin E, Reutfors J, Schmitt-Egenolf M, Lund LC, Houben E, Booth H, Calingaert B , Kaye JA, Gembert K, Rothman KJ , Dedman D, Kieler H, Gutierrez L , Hallas J, Perez-Gutthann S . To what extent are topical tacrolimus or pimecrolimus associated with an increased risk of skin cancer and lymphoma? Long-term results from JOELLE study . Poster presented at the 2020 Virtual European Academy of Dermatology and Venereology Conference; October 29, 2020. Previously presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management.
Darden C , Joish VN, Price MA , Garbinsky D , Schwartz S, Warner C, Wason S, Lapuerta P. Patient-reported activity impairment, work productivity loss, and carcinoid syndrome outcomes: interim analyses of the XERMELO patient registry . Poster presented at the NANETS 2020 Multidisciplinary Net Medical Virtual Symposium; October 2, 2020.
Richardson D , Zhan L, Reynolds M , Odom D , Hollis K , Mitra D, McRoy L, Hargis J. The impact of advanced or metastatic breast cancer or its treatment on productivity, energy, and physical activity among palbociclib participants of the MADELINE Study . Poster presented at the Virtual 12th European Breast Cancer Conference; October 2, 2020.
Arana A , Pottegard A, Kuiper JG, Crellin E, Reutfors J, Schmitt-Egenolf M, Lund LC, Houben E, Booth H, Calingaert B , Kaye JA, Gembert K, Rothman KJ , Dedman D, Kieler H, Gutierrez L , Hallas J, Perez-Gutthann S . To what extent are topical tacrolimus or pimecrolimus associated with increased risk of skin cancer and lymphoma? Long-term results from Joelle Study . Poster presented at the 2020 36th ICPE International Virtual Conference on Pharmacoepidemiology & Therapeutic Risk Management; September 16, 2020.